3,4,5-Tri-O-galloylquinic acidCAS# 99745-62-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 99745-62-7 | SDF | Download SDF |
| PubChem ID | 127406 | Appearance | Powder |
| Formula | C28H24O18 | M.Wt | 648.48 |
| Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
| Synonyms | (3r,5r)-1-hydroxy-3,4,5-tris[(3,4,5-trihydroxybenzoyl)oxy]cyclohexanecarboxylic acid | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3R,5R)-1-hydroxy-3,4,5-tris[(3,4,5-trihydroxybenzoyl)oxy]cyclohexane-1-carboxylic acid | ||
| SMILES | C1C(C(C(CC1(C(=O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O | ||
| Standard InChIKey | PEOHIPMSHPWYAQ-IOALSNHGSA-N | ||
| Standard InChI | InChI=1S/C28H24O18/c29-12-1-9(2-13(30)20(12)35)24(38)44-18-7-28(43,27(41)42)8-19(45-25(39)10-3-14(31)21(36)15(32)4-10)23(18)46-26(40)11-5-16(33)22(37)17(34)6-11/h1-6,18-19,23,29-37,43H,7-8H2,(H,41,42)/t18-,19-,23?,28?/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 3,5-Dicaffeoyl-epi-quinic acid shows anti-inflammatory activity, it may improve mast cell-mediated inflammatory diseases. |
| Targets | TNF-α | IL Receptor | JNK | Caspase | p38MAPK | Histamine Receptor |
3,4,5-Tri-O-galloylquinic acid Dilution Calculator
3,4,5-Tri-O-galloylquinic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5421 mL | 7.7103 mL | 15.4207 mL | 30.8414 mL | 38.5517 mL |
| 5 mM | 0.3084 mL | 1.5421 mL | 3.0841 mL | 6.1683 mL | 7.7103 mL |
| 10 mM | 0.1542 mL | 0.771 mL | 1.5421 mL | 3.0841 mL | 3.8552 mL |
| 50 mM | 0.0308 mL | 0.1542 mL | 0.3084 mL | 0.6168 mL | 0.771 mL |
| 100 mM | 0.0154 mL | 0.0771 mL | 0.1542 mL | 0.3084 mL | 0.3855 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Psoracorylifol C
Catalog No.:BCN3708
CAS No.:879290-99-0
- Psoracorylifol B
Catalog No.:BCN7884
CAS No.:879290-98-9
- Psoracorylifol A
Catalog No.:BCN3611
CAS No.:879290-97-8
- CP 93129 dihydrochloride
Catalog No.:BCC6899
CAS No.:879089-64-2
- GDC-0449 (Vismodegib)
Catalog No.:BCC1285
CAS No.:879085-55-9
- 15-deoxy-Δ-12,14-Prostaglandin J2
Catalog No.:BCC7321
CAS No.:87893-55-8
- AZ 628
Catalog No.:BCC3730
CAS No.:878739-06-1
- Lesinurad
Catalog No.:BCC1699
CAS No.:878672-00-5
- Fostriecin sodium salt
Catalog No.:BCC2460
CAS No.:87860-39-7
- WRW4
Catalog No.:BCC5893
CAS No.:878557-55-2
- JNJ 303
Catalog No.:BCC7806
CAS No.:878489-28-2
- Isosalviamine B
Catalog No.:BCN3554
CAS No.:878475-30-0
- p-Hydroxyphenethyl anisate
Catalog No.:BCN6896
CAS No.:87932-34-1
- Prionoid B
Catalog No.:BCN3217
CAS No.:879324-75-1
- Prionoid C
Catalog No.:BCN3159
CAS No.:879324-76-2
- Prionoid D
Catalog No.:BCN3160
CAS No.:879324-77-3
- Prionoid E
Catalog No.:BCN3161
CAS No.:879324-78-4
- UFP 803
Catalog No.:BCC5917
CAS No.:879497-82-2
- Ingenol-5,20-acetonide-3-O-angelate
Catalog No.:BCN8458
CAS No.:87980-68-5
- Furan-2-carboxylic acid
Catalog No.:BCN4557
CAS No.:88-14-2
- 2-Acetylthiophene
Catalog No.:BCC8517
CAS No.:88-15-3
- BHQ
Catalog No.:BCC6982
CAS No.:88-58-4
- 1,2-Benzenedicarboxylic acid
Catalog No.:BCN3151
CAS No.:88-99-3
- Neuropathiazol
Catalog No.:BCC5375
CAS No.:880090-88-0
Therapeutic effects of Artemisia scoparia Waldst. et Kitaib in a murine model of atopic dermatitis.[Pubmed:29740850]
Clin Exp Dermatol. 2018 Oct;43(7):798-805.
BACKGROUND: Artemisia scoparia Waldst. et Kitaib (AS) (Oriental wormwood, known as Bissuk in Korea) is a plant used in cosmetic and pharmaceutical treatments. However, the effect of AS on atopic dermatitis (AD) has not been described. AIM: To examine the inhibitory effect of AS on AD using a murine model. METHODS: We applied either AS, the butanol-extracted fraction of AS (Bu-OH) or 3,5-dicaffeoyl-epi-quinic acid (DEQA, a major component of Bu-OH) topically for 3 weeks to 2,4-dinitrofluorobenzene (DNFB)-induced skin lesions in BALB/c mice. RESULTS: AS, Bu-OH and DEQA suppressed the clinical symptoms of DNFB-induced skin lesions and he associated scratching behaviour. Numbers of inflammatory cells infiltrating skin lesions were significantly reduced by AS or Bu-OH application but not by DEQA. In addition, AS significantly suppressed serum levels of histamine and IgE, while Bu-OH significantly suppressed serum levels of histamine, IgE, thymic stromal lymphopoietin (TSLP), interleukin (IL)-4 and IL-6, and DEQA significantly suppressed serum levels of histamine, IgE, TSLP and IL-4 in DNFB-induced AD mice. In skin lesions, AS and Bu-OH significantly reduced inflammatory cytokines, whereas DEQA did not. AS, Bu-OH and DEQA all significantly suppressed caspase-1 activities. CONCLUSIONS: These results demonstrate the anti-AD effects of AS, Bu-OH and DEQA, and suggest that all three have therapeutic potential.
Anti-inflammatory effects of Artemisia scoparia and its active constituent, 3,5-dicaffeoyl-epi-quinic acid against activated mast cells.[Pubmed:29172841]
Immunopharmacol Immunotoxicol. 2018 Feb;40(1):52-58.
OBJECTIVES: Artemisia scoparia Waldst. et Kit. (AS) has been used to treat inflammation, urticaria and hepatitis. However, the scientific studies of AS and its active compound for inflammatory reactions in activated human mast cell line, HMC-1 cells have not yet been elucidated. MATERIALS AND METHODS: Here, we isolated 3,5-dicaffeoyl-epi-quinic acid (DEQA) from AS butanol fraction. The anti-inflammatory effect of AS and its new active compound, DEQA was examined in HMC-1 cells by studying the following markers: phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI)-induced thymic stromal lymphopoietin (TSLP), tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-6 secretion and mRNA expression by ELISA and RT-PCR, respectively. Furthermore, mechanism related to anti-inflammatory was examined by Western blotting. RESULTS: We reported that AS and its new active compound, DEQA significantly reduced TSLP, TNF-alpha, IL-1beta and IL-6 production levels through the reduction of caspase-1 activity. The mRNA expression of these inflammatory cytokine was also reduced via blocking nuclear factor-kappaB nuclear translocation by AS and DEQA. In addition, AS significantly reduced phosphorylated-c-Jun N-terminal kinase level and DEQA significantly reduced both phosphorylated-c-Jun N-terminal kinase and -p38 mitogen-activated protein kinase levels. CONCLUSIONS: Therefore, these results indicated that AS and its active compound, DEQA may improve mast cell-mediated inflammatory diseases.
